CoChat

Herceptin acts as an anti-angiogenic cocktail

Izumi, Yotaro, Xu, Lei, di Tomaso, Emmanuelle, Fukumura, Dai, Jain, Rakesh K. · 2002 · Nature

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Malignant tumours secrete factors that enable them to commandeer their own blood supply (angiogenesis), and blocking the action of these factors can inhibit tumour growth. But because tumours may become resistant to treatments that target individual angiogenic factors by switching over to other angiogenic molecules, a cocktail of multiple anti-angiogenic agents should be more effective. Here we show that herceptin, a monoclonal antibody against the cell-surface receptor HER2 (for human epidermal growth factor receptor-2; ref. 4), induces normalization and regression of the vasculature in an experimental human breast tumour that overexpresses HER2 in mice, and that it works by modulating the effects of different pro- and anti-angiogenic factors. As a single agent that acts against multiple targets, herceptin, or drugs like it, may offer a simple alternative to combination anti-angiogenic treatments.

Overview

Integrity signals

Registry

Crossref · 10.1038/416279b

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 11 references

Research works printed but not linked: 1

  1. Jain, R. K., Munn, L. L. & Fukumura, D. Nature Rev. Cancer (in the press).

Cited by

Items 201–300 of 622

Metadata

Authors
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K.
Affiliations
Harvard University (US)
Corresponding author
Jain, Rakesh K.
Venue
Nature
Published
2002-03
Volume
416
Issue
6878
Pages
279-280
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2034801324
Cited by
623
References
11
Citations by year
2026: 2 · 2025: 6 · 2024: 26 · 2023: 10 · 2022: 14 · 2021: 12 · 2020: 18 · 2019: 12 · 2018: 20 · 2017: 23 · 2016: 18 · 2015: 24 · 2014: 27 · 2013: 30 · 2012: 35
FWCI
12.17
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
Funders
National Cancer Institute (P01CA080124)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
Keywords
trastuzumab, anti-angiogenic therapy, HER2, human epidermal growth factor receptor 2, tumor angiogenesis, tumor regression, combination therapy, breast cancer, monoclonal antibodies, tumor resistance
MeSH terms
Trastuzumab, Animals, Antibodies, Monoclonal, Humans, Lymphokines, Mammary Neoplasms, Experimental, Neovascularization, Pathologic, Signal Transduction, Gene Expression, Endothelial Growth Factors, Mice, SCID, Genes, erbB-2, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Mice, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.